GlassScriptPhysician profile
Farheen Saeed
NPI 1326402504
$1,164.05
in general payments reported to CMS, 2019-2025
14 companies · $399 in 2025
The $399 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.86 · 2020: $392 · 2021: $112 · 2023: $88.41 · 2024: $123 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $295.65 | 2019-2025 | Ozempic |
| Amgen INC. | $165.32 | 2025 | Tepezza, Evenity, Repatha |
| Beta Bionics, INC. | $151.92 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $150.23 | 2020 | |
| Medtronic, INC. | $71.84 | 2023 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $64.05 | 2021-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.61 | 2021 | |
| Corcept Therapeutics | $47.23 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $41.15 | 2019-2025 | |
| Dexcom, INC. | $35.70 | 2020-2021 | |
| Horizon Therapeutics Plc | $33.54 | 2020 | |
| Radius Health, INC. | $19.38 | 2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $18.86 | 2019 | |
| Boston Scientific Corporation | $16.57 | 2023 | Watchman Flx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farheen Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.